Sublingual immunotherapy (SLIT) is a practical form of allergen immunotherapy. Studies using SLIT to dust mites are still needed to show the beneficial effect in adulthood and childhood asthma.
A cohort real-life study of 97 patients comparing the efficacy of SLIT between children 33% and adults 67% suffering from allergic rhinitis(AR) with its effect on asthma.The study is conducted at an outpatient clinic at Hotel Dieu de France Hospital (HDF), Beirut. Patients with AR monosensitized (74.3%) to dust mites, and suffering from mild to moderate asthma (50.5%), are evaluated. Evaluation is done at inclusion and at 36 months after SLIT. Patients received a standardized dust mites extract: StaloralR 300IR (Stallergenes) 4 pressions daily. Asthma symptom score (ASS), rhinitis symptom score (RTSS), asthma medication consumption score (AMCS) and Rhinitis medication consumption score (RMCS) are compared, prior to SLIT and 3 years after.
Using a t test, the average scores at inclusion and 36 months respectively were :In children RTSS: 17.75;5.75 (p<0.005), RMCS:5.923;0.923 (p<0.005), ASS:4.53;0.846 (p<0.005), AMCS:1.923;0.538 (p<0.005). In adults RTSS: 15.41;4.59 (p<0.005), RMCS: 6.73;1.86 (p<0.005), ASS: 5.636;0.773 (p<0.005), AMCS: 2.91;0.545 (p<0.005).The results of our study showed efficacy of SLIT for dust mites in both groups.
SLIT to dust mites is effective in both adults and children suffering from allergic rhinitis. It is also applicable in mild to moderate asthma. Most recent studies show that using high dose SLIT (8 pressions per day) may be more effective than the common regimen used above, further studies are required.